nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—amyotrophic lateral sclerosis	0.495	1	CbGaD
Mesalazine—Condition aggravated—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0349	CcSEcCtD
Mesalazine—Pneumonia aspiration—Riluzole—amyotrophic lateral sclerosis	0.00861	0.0292	CcSEcCtD
Mesalazine—PPARG—forelimb—amyotrophic lateral sclerosis	0.00787	0.13	CbGeAlD
Mesalazine—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.0072	0.0244	CcSEcCtD
Mesalazine—PPARG—hindlimb—amyotrophic lateral sclerosis	0.00708	0.117	CbGeAlD
Mesalazine—Rheumatoid arthritis—Riluzole—amyotrophic lateral sclerosis	0.00623	0.0211	CcSEcCtD
Mesalazine—PPARG—appendage—amyotrophic lateral sclerosis	0.00607	0.101	CbGeAlD
Mesalazine—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.0055	0.0186	CcSEcCtD
Mesalazine—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.00505	0.0171	CcSEcCtD
Mesalazine—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.00505	0.0171	CcSEcCtD
Mesalazine—Stiffness—Riluzole—amyotrophic lateral sclerosis	0.00495	0.0167	CcSEcCtD
Mesalazine—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00435	0.0147	CcSEcCtD
Mesalazine—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00401	0.0136	CcSEcCtD
Mesalazine—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.00389	0.0132	CcSEcCtD
Mesalazine—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00373	0.0126	CcSEcCtD
Mesalazine—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00373	0.0126	CcSEcCtD
Mesalazine—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00362	0.0599	CbGeAlD
Mesalazine—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00358	0.0121	CcSEcCtD
Mesalazine—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0116	CcSEcCtD
Mesalazine—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0116	CcSEcCtD
Mesalazine—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.0034	0.0115	CcSEcCtD
Mesalazine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00331	0.0112	CcSEcCtD
Mesalazine—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00327	0.0111	CcSEcCtD
Mesalazine—IKBKB—embryo—amyotrophic lateral sclerosis	0.00324	0.0537	CbGeAlD
Mesalazine—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.0032	0.0108	CcSEcCtD
Mesalazine—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0107	CcSEcCtD
Mesalazine—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00313	0.0106	CcSEcCtD
Mesalazine—PTGS2—appendage—amyotrophic lateral sclerosis	0.0031	0.0514	CbGeAlD
Mesalazine—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0101	CcSEcCtD
Mesalazine—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00296	0.01	CcSEcCtD
Mesalazine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00972	CcSEcCtD
Mesalazine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00276	0.00934	CcSEcCtD
Mesalazine—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00899	CcSEcCtD
Mesalazine—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00899	CcSEcCtD
Mesalazine—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00899	CcSEcCtD
Mesalazine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00891	CcSEcCtD
Mesalazine—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00831	CcSEcCtD
Mesalazine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00824	CcSEcCtD
Mesalazine—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00774	CcSEcCtD
Mesalazine—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00757	CcSEcCtD
Mesalazine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00219	0.0074	CcSEcCtD
Mesalazine—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0073	CcSEcCtD
Mesalazine—CHUK—cerebellum—amyotrophic lateral sclerosis	0.00215	0.0357	CbGeAlD
Mesalazine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00725	CcSEcCtD
Mesalazine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0071	CcSEcCtD
Mesalazine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00705	CcSEcCtD
Mesalazine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00207	0.007	CcSEcCtD
Mesalazine—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00695	CcSEcCtD
Mesalazine—PPARG—embryo—amyotrophic lateral sclerosis	0.00202	0.0334	CbGeAlD
Mesalazine—Gout—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00682	CcSEcCtD
Mesalazine—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.002	0.00677	CcSEcCtD
Mesalazine—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00673	CcSEcCtD
Mesalazine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00644	CcSEcCtD
Mesalazine—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00637	CcSEcCtD
Mesalazine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00637	CcSEcCtD
Mesalazine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00629	CcSEcCtD
Mesalazine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00622	CcSEcCtD
Mesalazine—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00608	CcSEcCtD
Mesalazine—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00598	CcSEcCtD
Mesalazine—CHUK—brain—amyotrophic lateral sclerosis	0.00175	0.029	CbGeAlD
Mesalazine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00585	CcSEcCtD
Mesalazine—Coma—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00582	CcSEcCtD
Mesalazine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00576	CcSEcCtD
Mesalazine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00558	CcSEcCtD
Mesalazine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00542	CcSEcCtD
Mesalazine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00542	CcSEcCtD
Mesalazine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00531	CcSEcCtD
Mesalazine—IKBKB—nervous system—amyotrophic lateral sclerosis	0.00156	0.0258	CbGeAlD
Mesalazine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00526	CcSEcCtD
Mesalazine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00517	CcSEcCtD
Mesalazine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00514	CcSEcCtD
Mesalazine—IKBKB—central nervous system—amyotrophic lateral sclerosis	0.0015	0.0248	CbGeAlD
Mesalazine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00498	CcSEcCtD
Mesalazine—IKBKB—cerebellum—amyotrophic lateral sclerosis	0.00146	0.0243	CbGeAlD
Mesalazine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00492	CcSEcCtD
Mesalazine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00488	CcSEcCtD
Mesalazine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00486	CcSEcCtD
Mesalazine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00475	CcSEcCtD
Mesalazine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00462	CcSEcCtD
Mesalazine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00462	CcSEcCtD
Mesalazine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00458	CcSEcCtD
Mesalazine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00455	CcSEcCtD
Mesalazine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00455	CcSEcCtD
Mesalazine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00446	CcSEcCtD
Mesalazine—MPO—spinal cord—amyotrophic lateral sclerosis	0.00129	0.0215	CbGeAlD
Mesalazine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00438	CcSEcCtD
Mesalazine—ALOX5—nervous system—amyotrophic lateral sclerosis	0.00129	0.0214	CbGeAlD
Mesalazine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00427	CcSEcCtD
Mesalazine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00422	CcSEcCtD
Mesalazine—ALOX5—central nervous system—amyotrophic lateral sclerosis	0.00124	0.0206	CbGeAlD
Mesalazine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00418	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00416	CcSEcCtD
Mesalazine—ALOX5—cerebellum—amyotrophic lateral sclerosis	0.00121	0.0201	CbGeAlD
Mesalazine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00409	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00408	CcSEcCtD
Mesalazine—IKBKB—brain—amyotrophic lateral sclerosis	0.00119	0.0197	CbGeAlD
Mesalazine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00402	CcSEcCtD
Mesalazine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00399	CcSEcCtD
Mesalazine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00399	CcSEcCtD
Mesalazine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00399	CcSEcCtD
Mesalazine—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00392	CcSEcCtD
Mesalazine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00389	CcSEcCtD
Mesalazine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00384	CcSEcCtD
Mesalazine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00383	CcSEcCtD
Mesalazine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00379	CcSEcCtD
Mesalazine—Salicylate-sodium—PTGS2—amyotrophic lateral sclerosis	0.00111	0.3	CrCbGaD
Mesalazine—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00373	CcSEcCtD
Mesalazine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00373	CcSEcCtD
Mesalazine—MPO—nervous system—amyotrophic lateral sclerosis	0.00109	0.0181	CbGeAlD
Mesalazine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00369	CcSEcCtD
Mesalazine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00365	CcSEcCtD
Mesalazine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00363	CcSEcCtD
Mesalazine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00361	CcSEcCtD
Mesalazine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00358	CcSEcCtD
Mesalazine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00356	CcSEcCtD
Mesalazine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00356	CcSEcCtD
Mesalazine—MPO—central nervous system—amyotrophic lateral sclerosis	0.00105	0.0174	CbGeAlD
Mesalazine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00355	CcSEcCtD
Mesalazine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00349	CcSEcCtD
Mesalazine—PTGS2—embryo—amyotrophic lateral sclerosis	0.00103	0.0171	CbGeAlD
Mesalazine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00347	CcSEcCtD
Mesalazine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00347	CcSEcCtD
Mesalazine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00346	CcSEcCtD
Mesalazine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00341	CcSEcCtD
Mesalazine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.001	0.0034	CcSEcCtD
Mesalazine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000995	0.00337	CcSEcCtD
Mesalazine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000992	0.00336	CcSEcCtD
Mesalazine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000987	0.00334	CcSEcCtD
Mesalazine—ALOX5—brain—amyotrophic lateral sclerosis	0.000985	0.0163	CbGeAlD
Mesalazine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000982	0.00332	CcSEcCtD
Mesalazine—PPARG—nervous system—amyotrophic lateral sclerosis	0.000968	0.016	CbGeAlD
Mesalazine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00321	CcSEcCtD
Mesalazine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000947	0.00321	CcSEcCtD
Mesalazine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000944	0.0032	CcSEcCtD
Mesalazine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000944	0.0032	CcSEcCtD
Mesalazine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000937	0.00317	CcSEcCtD
Mesalazine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000933	0.00316	CcSEcCtD
Mesalazine—PPARG—central nervous system—amyotrophic lateral sclerosis	0.000932	0.0154	CbGeAlD
Mesalazine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00093	0.00315	CcSEcCtD
Mesalazine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000928	0.00314	CcSEcCtD
Mesalazine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000926	0.00313	CcSEcCtD
Mesalazine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00302	CcSEcCtD
Mesalazine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00299	CcSEcCtD
Mesalazine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00297	CcSEcCtD
Mesalazine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000857	0.0029	CcSEcCtD
Mesalazine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000853	0.00289	CcSEcCtD
Mesalazine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000851	0.00288	CcSEcCtD
Mesalazine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000847	0.00287	CcSEcCtD
Mesalazine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000834	0.00283	CcSEcCtD
Mesalazine—MPO—brain—amyotrophic lateral sclerosis	0.000834	0.0138	CbGeAlD
Mesalazine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000827	0.0028	CcSEcCtD
Mesalazine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00081	0.00274	CcSEcCtD
Mesalazine—Tension—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00273	CcSEcCtD
Mesalazine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00273	CcSEcCtD
Mesalazine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000798	0.0027	CcSEcCtD
Mesalazine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000795	0.00269	CcSEcCtD
Mesalazine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00268	CcSEcCtD
Mesalazine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00261	CcSEcCtD
Mesalazine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00258	CcSEcCtD
Mesalazine—Olsalazine—PTGS2—amyotrophic lateral sclerosis	0.000762	0.206	CrCbGaD
Mesalazine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00257	CcSEcCtD
Mesalazine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000751	0.00254	CcSEcCtD
Mesalazine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00251	CcSEcCtD
Mesalazine—PPARG—brain—amyotrophic lateral sclerosis	0.00074	0.0123	CbGeAlD
Mesalazine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000739	0.0025	CcSEcCtD
Mesalazine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000737	0.0025	CcSEcCtD
Mesalazine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000736	0.00249	CcSEcCtD
Mesalazine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00246	CcSEcCtD
Mesalazine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000723	0.00245	CcSEcCtD
Mesalazine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000717	0.00243	CcSEcCtD
Mesalazine—Aminosalicylic Acid—PTGS2—amyotrophic lateral sclerosis	0.000716	0.193	CrCbGaD
Mesalazine—Diflunisal—PTGS2—amyotrophic lateral sclerosis	0.000716	0.193	CrCbGaD
Mesalazine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00071	0.0024	CcSEcCtD
Mesalazine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00237	CcSEcCtD
Mesalazine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00237	CcSEcCtD
Mesalazine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00237	CcSEcCtD
Mesalazine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000697	0.00236	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000695	0.00235	CcSEcCtD
Mesalazine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000691	0.00234	CcSEcCtD
Mesalazine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000684	0.00232	CcSEcCtD
Mesalazine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00229	CcSEcCtD
Mesalazine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000671	0.00227	CcSEcCtD
Mesalazine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000671	0.00227	CcSEcCtD
Mesalazine—Infection—Riluzole—amyotrophic lateral sclerosis	0.000667	0.00226	CcSEcCtD
Mesalazine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00066	0.00223	CcSEcCtD
Mesalazine—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000658	0.0109	CbGeAlD
Mesalazine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000658	0.00223	CcSEcCtD
Mesalazine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00222	CcSEcCtD
Mesalazine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000655	0.00222	CcSEcCtD
Mesalazine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000652	0.00221	CcSEcCtD
Mesalazine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000649	0.0022	CcSEcCtD
Mesalazine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00064	0.00217	CcSEcCtD
Mesalazine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00212	CcSEcCtD
Mesalazine—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000614	0.0102	CbGeAlD
Mesalazine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00207	CcSEcCtD
Mesalazine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000607	0.00205	CcSEcCtD
Mesalazine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000602	0.00204	CcSEcCtD
Mesalazine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00202	CcSEcCtD
Mesalazine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000596	0.00202	CcSEcCtD
Mesalazine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000591	0.002	CcSEcCtD
Mesalazine—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000587	0.00973	CbGeAlD
Mesalazine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000583	0.00197	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000579	0.00196	CcSEcCtD
Mesalazine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000578	0.00196	CcSEcCtD
Mesalazine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000574	0.00194	CcSEcCtD
Mesalazine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000574	0.00194	CcSEcCtD
Mesalazine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000553	0.00187	CcSEcCtD
Mesalazine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000549	0.00186	CcSEcCtD
Mesalazine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000533	0.0018	CcSEcCtD
Mesalazine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00053	0.0018	CcSEcCtD
Mesalazine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00053	0.0018	CcSEcCtD
Mesalazine—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000517	0.00858	CbGeAlD
Mesalazine—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000498	0.00826	CbGeAlD
Mesalazine—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000495	0.0082	CbGeAlD
Mesalazine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00167	CcSEcCtD
Mesalazine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000481	0.00163	CcSEcCtD
Mesalazine—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000476	0.00789	CbGeAlD
Mesalazine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00161	CcSEcCtD
Mesalazine—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000465	0.00771	CbGeAlD
Mesalazine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000459	0.00155	CcSEcCtD
Mesalazine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000444	0.0015	CcSEcCtD
Mesalazine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00144	CcSEcCtD
Mesalazine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00143	CcSEcCtD
Mesalazine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00143	CcSEcCtD
Mesalazine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00042	0.00142	CcSEcCtD
Mesalazine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000399	0.00135	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—amyotrophic lateral sclerosis	0.000398	0.108	CrCbGaD
Mesalazine—PTGS1—brain—amyotrophic lateral sclerosis	0.000396	0.00655	CbGeAlD
Mesalazine—PTGS2—brain—amyotrophic lateral sclerosis	0.000378	0.00627	CbGeAlD
Mesalazine—CHUK—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000223	0.00153	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000223	0.00153	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000222	0.00152	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—CASP9—amyotrophic lateral sclerosis	0.000221	0.00152	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.00022	0.00151	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—IGF1—amyotrophic lateral sclerosis	0.00022	0.00151	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.00022	0.00151	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00022	0.00151	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—amyotrophic lateral sclerosis	0.000219	0.0015	CbGpPWpGaD
Mesalazine—CHUK—p75(NTR)-mediated signaling—CASP3—amyotrophic lateral sclerosis	0.000218	0.0015	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000216	0.00148	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	0.000214	0.00147	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000212	0.00146	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000209	0.00143	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000209	0.00143	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000209	0.00143	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—DAO—amyotrophic lateral sclerosis	0.000208	0.00143	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.000207	0.00142	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000205	0.00141	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	0.000205	0.00141	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—CASP9—amyotrophic lateral sclerosis	0.000205	0.00141	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000204	0.0014	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000204	0.0014	CbGpPWpGaD
Mesalazine—CHUK—Disease—TPK1—amyotrophic lateral sclerosis	0.0002	0.00137	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—amyotrophic lateral sclerosis	0.000198	0.00136	CbGpPWpGaD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—CASP3—amyotrophic lateral sclerosis	0.000198	0.00136	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—BDNF—amyotrophic lateral sclerosis	0.000195	0.00133	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	0.000194	0.00133	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000194	0.00133	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—ERBB4—amyotrophic lateral sclerosis	0.000193	0.00133	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000193	0.00132	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00019	0.0013	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000189	0.0013	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—SQSTM1—amyotrophic lateral sclerosis	0.000189	0.0013	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000187	0.00128	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000187	0.00128	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000186	0.00128	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000185	0.00127	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000185	0.00127	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000182	0.00125	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000178	0.00122	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000178	0.00122	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000178	0.00122	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000176	0.00121	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—ERBB4—amyotrophic lateral sclerosis	0.000175	0.0012	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000175	0.0012	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000173	0.00119	CbGpPWpGaD
Mesalazine—IKBKB—p75 NTR receptor-mediated signalling—CASP3—amyotrophic lateral sclerosis	0.000172	0.00118	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—SQSTM1—amyotrophic lateral sclerosis	0.000172	0.00118	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000169	0.00116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000169	0.00116	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000169	0.00116	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000167	0.00115	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000166	0.00114	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000166	0.00114	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000164	0.00113	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000163	0.00112	CbGpPWpGaD
Mesalazine—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000163	0.00112	CbGpPWpGaD
Mesalazine—CHUK—Disease—VTA1—amyotrophic lateral sclerosis	0.00016	0.0011	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.00016	0.0011	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000159	0.00109	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—CASP3—amyotrophic lateral sclerosis	0.000159	0.00109	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000158	0.00109	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000158	0.00108	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000157	0.00108	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000154	0.00106	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000152	0.00104	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000152	0.00104	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000151	0.00103	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000149	0.00102	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000148	0.00101	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GSR—amyotrophic lateral sclerosis	0.000146	0.001	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000145	0.000993	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000145	0.000991	CbGpPWpGaD
Mesalazine—CHUK—Rac1/Pak1/p38/MMP-2 pathway—TP53—amyotrophic lateral sclerosis	0.000143	0.000984	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.000143	0.000983	CbGpPWpGaD
Mesalazine—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000143	0.00098	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000143	0.000979	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000142	0.000976	CbGpPWpGaD
Mesalazine—CHUK—p75(NTR)-mediated signaling—TP53—amyotrophic lateral sclerosis	0.00014	0.000961	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000136	0.000933	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000133	0.000911	CbGpPWpGaD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—amyotrophic lateral sclerosis	0.00013	0.000892	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—DAO—amyotrophic lateral sclerosis	0.000129	0.000885	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000129	0.000885	CbGpPWpGaD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—TP53—amyotrophic lateral sclerosis	0.000127	0.000871	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000126	0.000862	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000125	0.000858	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000125	0.000858	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000122	0.000838	CbGpPWpGaD
Mesalazine—CHUK—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000121	0.000832	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000121	0.000832	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000121	0.000827	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00012	0.000822	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TP53—amyotrophic lateral sclerosis	0.00012	0.000821	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	0.000119	0.000813	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000117	0.000801	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000117	0.0008	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000117	0.000799	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000115	0.000787	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000114	0.000785	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.00011	0.000754	CbGpPWpGaD
Mesalazine—CHUK—Disease—PLB1—amyotrophic lateral sclerosis	0.00011	0.000752	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000109	0.000751	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000109	0.00075	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TP53—amyotrophic lateral sclerosis	0.000108	0.000744	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000106	0.000729	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000104	0.000715	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—TP53—amyotrophic lateral sclerosis	0.000102	0.000698	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.0001	0.000686	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ATF1—amyotrophic lateral sclerosis	9.96e-05	0.000683	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	9.93e-05	0.000681	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	9.93e-05	0.000681	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	9.9e-05	0.00068	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PLB1—amyotrophic lateral sclerosis	9.78e-05	0.000671	CbGpPWpGaD
Mesalazine—CHUK—Disease—VCP—amyotrophic lateral sclerosis	9.77e-05	0.00067	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	9.72e-05	0.000667	CbGpPWpGaD
Mesalazine—CHUK—Immune System—DCTN1—amyotrophic lateral sclerosis	9.68e-05	0.000664	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	9.67e-05	0.000664	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CASP9—amyotrophic lateral sclerosis	9.48e-05	0.000651	CbGpPWpGaD
Mesalazine—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	9.48e-05	0.00065	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.26e-05	0.000635	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	9.11e-05	0.000625	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	9.08e-05	0.000623	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	9.04e-05	0.00062	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ATF1—amyotrophic lateral sclerosis	9.03e-05	0.000619	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSR—amyotrophic lateral sclerosis	9.03e-05	0.000619	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—DCTN1—amyotrophic lateral sclerosis	8.78e-05	0.000602	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CASP9—amyotrophic lateral sclerosis	8.6e-05	0.00059	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.44e-05	0.000579	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	8.42e-05	0.000578	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	8.26e-05	0.000567	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.22e-05	0.000564	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	8.21e-05	0.000563	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	8.12e-05	0.000557	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	7.96e-05	0.000546	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	7.94e-05	0.000544	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	7.79e-05	0.000535	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.68e-05	0.000527	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.49e-05	0.000514	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.48e-05	0.000513	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	7.44e-05	0.000511	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CHAT—amyotrophic lateral sclerosis	7.41e-05	0.000509	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	7.36e-05	0.000505	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	7.33e-05	0.000503	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.22e-05	0.000495	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	7.18e-05	0.000493	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	7.18e-05	0.000492	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	7.07e-05	0.000485	CbGpPWpGaD
Mesalazine—CHUK—Disease—CST3—amyotrophic lateral sclerosis	7.01e-05	0.000481	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	7e-05	0.00048	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	6.96e-05	0.000478	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	6.85e-05	0.00047	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.84e-05	0.00047	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.76e-05	0.000464	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—C3—amyotrophic lateral sclerosis	6.74e-05	0.000463	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	6.64e-05	0.000456	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.63e-05	0.000455	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.55e-05	0.000449	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	6.49e-05	0.000446	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—C3—amyotrophic lateral sclerosis	6.48e-05	0.000444	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.44e-05	0.000442	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	6.35e-05	0.000436	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	6.34e-05	0.000435	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	6.32e-05	0.000434	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	6.23e-05	0.000427	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.2e-05	0.000426	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	6.2e-05	0.000425	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SQSTM1—amyotrophic lateral sclerosis	6.18e-05	0.000424	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—C3—amyotrophic lateral sclerosis	6.12e-05	0.00042	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.01e-05	0.000412	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.91e-05	0.000406	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.88e-05	0.000404	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—C3—amyotrophic lateral sclerosis	5.87e-05	0.000403	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.82e-05	0.000399	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ATF1—amyotrophic lateral sclerosis	5.8e-05	0.000398	CbGpPWpGaD
Mesalazine—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	5.79e-05	0.000397	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.76e-05	0.000395	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.73e-05	0.000393	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SQSTM1—amyotrophic lateral sclerosis	5.61e-05	0.000385	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CASP9—amyotrophic lateral sclerosis	5.52e-05	0.000379	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.44e-05	0.000373	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	5.4e-05	0.00037	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.34e-05	0.000366	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.28e-05	0.000362	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ATF1—amyotrophic lateral sclerosis	5.26e-05	0.000361	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.19e-05	0.000356	CbGpPWpGaD
Mesalazine—CHUK—Disease—CASP9—amyotrophic lateral sclerosis	5.1e-05	0.00035	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	5.02e-05	0.000344	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CASP9—amyotrophic lateral sclerosis	5.01e-05	0.000344	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—APOE—amyotrophic lateral sclerosis	4.87e-05	0.000334	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.86e-05	0.000334	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.74e-05	0.000325	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB4—amyotrophic lateral sclerosis	4.73e-05	0.000324	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.63e-05	0.000318	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.57e-05	0.000314	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.55e-05	0.000312	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD40LG—amyotrophic lateral sclerosis	4.44e-05	0.000305	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB4—amyotrophic lateral sclerosis	4.36e-05	0.000299	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB4—amyotrophic lateral sclerosis	4.29e-05	0.000294	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	4.15e-05	0.000285	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.12e-05	0.000283	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	4.09e-05	0.00028	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40LG—amyotrophic lateral sclerosis	4.03e-05	0.000277	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4e-05	0.000274	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.98e-05	0.000273	CbGpPWpGaD
Mesalazine—CHUK—Immune System—C3—amyotrophic lateral sclerosis	3.93e-05	0.00027	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.76e-05	0.000258	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.75e-05	0.000257	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.67e-05	0.000252	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.66e-05	0.000251	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.62e-05	0.000249	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.57e-05	0.000245	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—C3—amyotrophic lateral sclerosis	3.56e-05	0.000244	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.4e-05	0.000233	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOE—amyotrophic lateral sclerosis	3.38e-05	0.000232	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.33e-05	0.000229	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.25e-05	0.000223	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.24e-05	0.000222	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.06e-05	0.00021	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	3.02e-05	0.000207	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—amyotrophic lateral sclerosis	3.01e-05	0.000207	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.87e-05	0.000197	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.79e-05	0.000191	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.77e-05	0.00019	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.61e-05	0.000179	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	2.59e-05	0.000177	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.56e-05	0.000176	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.54e-05	0.000174	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.36e-05	0.000162	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—amyotrophic lateral sclerosis	2.31e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.3e-05	0.000158	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.22e-05	0.000152	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.14e-05	0.000147	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	2.11e-05	0.000145	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.06e-05	0.000142	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.04e-05	0.00014	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	2e-05	0.000137	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.95e-05	0.000134	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.77e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.67e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.5e-05	0.000103	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.45e-05	9.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.42e-05	9.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.36e-05	9.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.29e-05	8.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.28e-05	8.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.16e-05	7.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.64e-06	6.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.74e-06	6e-05	CbGpPWpGaD
